15 / 28
a
Based on July 12, 2017, data cut.
b
Last tumour assessment was < 20 days before final dose.
c
Ongoing response refers to no PD or death. Ongoing response symbol does not imply timing.
d
As of July 12, 2017, data cut. Thin bars refer to on-study period following final treatment
.
•
Many responders experienced
long-term responses
•
Patients who experienced
responses > 4 mo after starting
treatment still experienced long-
term benefit
•
In responders with tumour
assessments after treatment
discontinuation (n = 11), post-
discontinuation DOR ranged from
1.3 to 27.1+ mo
•
5 of these patients had been off
treatment for
> 1 year (≤ 27 mo)
15
Efficacy by PD-L1 Status as of Most Recent Analysis
Duration of treatment and response
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
X
Patient with IC0 or IC1 tumour
Patient with IC2/3 tumour
▌
First IRF-assessed PR/CR
>
Ongoing response as of last assessment
c
■
IRF-assessed RECIST v1.1 PD
X
Final treatment dose
d
○
Death
Presentado por I Durán et al. GCBC 2018.